RS54901B1 - Biciklično supstituisani uracili i njihova upotreba - Google Patents

Biciklično supstituisani uracili i njihova upotreba

Info

Publication number
RS54901B1
RS54901B1 RS20160510A RSP20160510A RS54901B1 RS 54901 B1 RS54901 B1 RS 54901B1 RS 20160510 A RS20160510 A RS 20160510A RS P20160510 A RSP20160510 A RS P20160510A RS 54901 B1 RS54901 B1 RS 54901B1
Authority
RS
Serbia
Prior art keywords
alkyl
halogen
hydrogen
trifluoromethyl
difluoromethyl
Prior art date
Application number
RS20160510A
Other languages
English (en)
Inventor
Chantal Fürstner
Jens Ackerstaff
Alexander Straub
Heinrich Meier
Hanna Tinel
Katja Zimmermann
Adrian Tersteegen
Dmitry Zubov
Raimund Kast
Jens Schamberger
Martina Schäfer
Kirsten Börngen
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of RS54901B1 publication Critical patent/RS54901B1/sr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/5381,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Jedinjenje sa formulom (I)naznačeno time štoR1 je vodonik ili (C1-C4)-alkil,gde* je mesto spajanja na atom azota na uracilu,A je -CH2-, -CH2-CH2-, - O-CH2-## ili kiseonik, gde## je mesto spajanja na fenil prsten,m je broj 0, 1 ili 2,R4 je halogen, difluorometil, trifluorometil, (C1-C4)-alkil, difluorometoksi,trifluorometoksi ili (C1-C4)-alkoksi,R3A je vodonik ili deuterijum,R5B je vodonik, deuterijum ili (C1-C4)-alkil,R6 je vodonik ili fluor,R7 je vodonik ili fluor,R8 je halogen, difluorometil, trifiuorometil, (C1-C4)-alkil ili nitro,R9 je vodonik, halogen, difluorometil, trifluorometil, (C1-C4)-alkil, nitro ili (C1-C4)-alkiltio,R3 je grupa sa formulomgde# je mesto spajanja na atom azota na uracilu,prsten Q je 5- do 7-člani heterociklil ili 5- ili 6-člani heteroaril,gde 5- do 7-člani heterociklil i 5- ili 6-člani heteroaril može biti supstituisan sa 1 do 4 supstituenata koji su nezavisno izabrani iz grupe koja obuhvata halogen, difluorometil, trifluorometil, trideuterometil, (C1-C6)-alkil, (C3-C7)-cikloalkil, okso, hidroksil, (C1-C4)-alkilkarbonil, (C1-C4)-alkoksikarbonil, aminokarbonil i (C1-C4)-alkilsulfonil,gde (C1-C6)-alkil i (C3-C7)-cikloalkil mogu opet da budu supstituisani sa 1 do 3 supstituenata koji su nezavisno izabrani iz grupe koja obuhvata halogen, cijano, trifluorometil, (C3-C7)-cikloalkil, hidroksil, (C1-C4)-alkoksi i 4- do 7-člani heterociklil, igde dva (C1-C6)-alkil radikala vezana na atom ugljenika u 5- do 7-članom heterociklilu i 5- ili 6-članom heteroarilu, zajedno sa atomom ugljenika na koji su vezani, mogu da grade 3- do 6-člani karbocikl,R24 je halogen, (C1-C4)-alkil ili (C1-C4)-alkoksi,n je broj 0, 1, 2 ili 3,i soli, solvati i solvati njihovih soli.Prijava sadrži još 16 patentnih zahteva.
RS20160510A 2012-05-09 2013-05-03 Biciklično supstituisani uracili i njihova upotreba RS54901B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12167231 2012-05-09
EP13720407.9A EP2847190B1 (de) 2012-05-09 2013-05-03 Bicyclisch-substituierte uracile und ihre verwendung
PCT/EP2013/059286 WO2013167495A1 (de) 2012-05-09 2013-05-03 Bicyclisch-substituierte uracile und ihre verwendung

Publications (1)

Publication Number Publication Date
RS54901B1 true RS54901B1 (sr) 2016-10-31

Family

ID=48289199

Family Applications (2)

Application Number Title Priority Date Filing Date
RS20180076A RS56784B1 (sr) 2012-05-09 2013-05-03 Biciklično supstituisani uracili i njihova upotreba
RS20160510A RS54901B1 (sr) 2012-05-09 2013-05-03 Biciklično supstituisani uracili i njihova upotreba

Family Applications Before (1)

Application Number Title Priority Date Filing Date
RS20180076A RS56784B1 (sr) 2012-05-09 2013-05-03 Biciklično supstituisani uracili i njihova upotreba

Country Status (44)

Country Link
US (5) US9481672B2 (sr)
EP (2) EP3045456B1 (sr)
JP (2) JP6141414B2 (sr)
KR (1) KR102083281B1 (sr)
CN (2) CN106983751B (sr)
AP (1) AP2014008096A0 (sr)
AR (1) AR090994A1 (sr)
AU (2) AU2013258223B2 (sr)
BR (1) BR112014028086B1 (sr)
CA (1) CA2872906C (sr)
CL (1) CL2014003031A1 (sr)
CO (1) CO7131375A2 (sr)
CR (1) CR20140513A (sr)
CU (1) CU20140129A7 (sr)
CY (2) CY1118900T1 (sr)
DK (2) DK2847190T3 (sr)
DO (1) DOP2014000255A (sr)
EA (2) EA031222B1 (sr)
EC (1) ECSP14026138A (sr)
ES (2) ES2657315T3 (sr)
HK (1) HK1202873A1 (sr)
HR (2) HRP20160796T1 (sr)
HU (2) HUE035462T2 (sr)
IL (2) IL235438A (sr)
JO (1) JO3290B1 (sr)
LT (1) LT3045456T (sr)
MX (2) MX367599B (sr)
MY (1) MY181828A (sr)
NO (1) NO3045456T3 (sr)
NZ (1) NZ701700A (sr)
PE (1) PE20142301A1 (sr)
PH (1) PH12014502496A1 (sr)
PL (2) PL3045456T3 (sr)
PT (2) PT2847190T (sr)
RS (2) RS56784B1 (sr)
SA (1) SA113340533B1 (sr)
SG (1) SG10202003175QA (sr)
SI (2) SI2847190T1 (sr)
TN (1) TN2014000470A1 (sr)
TW (2) TWI579278B (sr)
UA (1) UA112897C2 (sr)
UY (1) UY34797A (sr)
WO (1) WO2013167495A1 (sr)
ZA (1) ZA201408146B (sr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA112897C2 (uk) * 2012-05-09 2016-11-10 Байєр Фарма Акцієнгезелльшафт Біциклічно заміщені урацили та їх застосування для лікування і/або профілактики захворювань
EP3066097B1 (de) * 2013-11-08 2017-08-16 Bayer Pharma Aktiengesellschaft Salze von 1-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-6-yl)-2,4-dioxo-3-[(1r)-4-(trifluormethyl)-2,3-dihydro-1h-inden-1-yl]-1,2,3,4-tetrahydropyrimidin-5-carbonsäure
WO2015067650A1 (de) * 2013-11-08 2015-05-14 Bayer Pharma Aktiengesellschaft Substituierte 1,2,4-triazin-3,5-dione und ihre verwendung als chymase hemmern
EP3066098A1 (de) * 2013-11-08 2016-09-14 Bayer Pharma Aktiengesellschaft Substituierte uracile und ihre verwendung
CN105873919A (zh) * 2013-11-08 2016-08-17 拜耳医药股份有限公司 作为类糜蛋白酶抑制剂的取代的尿嘧啶
WO2017162661A1 (en) 2016-03-22 2017-09-28 Bayer Pharma Aktiengesellschaft 1h-benzo[de]isoquinoline-1,3(2h)-diones
EP3338780A1 (de) 2016-12-20 2018-06-27 Bayer Pharma Aktiengesellschaft Verwendung von chymaseinhibitoren zur behandlung von endometriose, post-operativer fibrose und erkrankungen die durch fibrosebildung gekennzeichnet sind
CA3061444A1 (en) 2017-04-27 2018-11-01 Bayer Aktiengesellschaft Selective adrenoreceptor .alpha.2c receptor antagonists alone, or in combination with chymase inhibitors for use in the treatment and/or prophylaxis of peripheral artery diseases (pad)
BR112020022340A2 (pt) 2018-05-15 2021-02-02 Bayer Aktiengesellschaft benzamidas substituídas por 1,3-tiazol-2-il para o tratamento de doenças associadas com sensibilização de fibras nervosas
CN110229067A (zh) * 2019-06-05 2019-09-13 南京焕然生物科技有限公司 一种2-氨基茚制备方法
CN113811530B (zh) * 2019-07-03 2022-07-19 南京明德新药研发有限公司 作为糜酶抑制剂的嘧啶酮类化合物及其应用
CN111440141A (zh) * 2020-05-20 2020-07-24 安徽泽升科技有限公司 一种羟甲基取代芳杂环类化合物的制备方法
WO2022135534A1 (zh) * 2020-12-25 2022-06-30 广东东阳光药业有限公司 取代的含氮双环化合物及其用途
CN114671856B (zh) * 2020-12-25 2023-10-20 广东东阳光药业股份有限公司 多取代的尿嘧啶衍生物及其用途
WO2022135514A1 (zh) * 2020-12-25 2022-06-30 广东东阳光药业有限公司 多取代的尿嘧啶衍生物及其用途
TW202339706A (zh) * 2021-12-06 2023-10-16 美商普萊萃歐治療公司 含醯胺的lonp1抑制劑化合物、用途及方法
US11618751B1 (en) 2022-03-25 2023-04-04 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
TW202404601A (zh) 2022-04-05 2024-02-01 加拿大商索科普拉健康與人類科學兩合公司 用於選擇性消退血栓性或血栓栓塞性疾病中血栓的凝乳酶抑制劑

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6403599B1 (en) * 1995-11-08 2002-06-11 Pfizer Inc Corticotropin releasing factor antagonists
US6114532A (en) 1998-02-03 2000-09-05 Boehringer Ingelheim Pharma Kg Bicyclic heterocycles, the preparation thereof, and their use as pharmaceuticals
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
US6458952B1 (en) 1999-05-19 2002-10-01 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl uracils useful for selective inhibition of the coagulation cascade
EP1219611A4 (en) 1999-09-03 2003-03-19 Ajinomoto Kk NEW PROCESSES FOR THE PRODUCTION OF OXAZEPINE DERIVATIVES
DE19943636A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943639A1 (de) 1999-09-13 2001-03-15 Bayer Ag Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften
DE19943634A1 (de) 1999-09-13 2001-04-12 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
GB0021315D0 (en) * 2000-08-30 2000-10-18 Dainippon Pharmaceutical Co Heterocyclic compounds and intermediates thereof
AR031176A1 (es) 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
DE10110749A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte Aminodicarbonsäurederivate
DE10110750A1 (de) 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
JP2003017508A (ja) 2001-07-05 2003-01-17 Nec Corp 電界効果トランジスタ
AR038536A1 (es) 2002-02-25 2005-01-19 Upjohn Co N-aril-2-oxazolidinona-5- carboxamidas y sus derivados
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
JP2003342265A (ja) * 2002-05-22 2003-12-03 Senju Pharmaceut Co Ltd トリアゾリジン誘導体およびその医薬用途
AU2003290735A1 (en) 2002-12-06 2004-06-30 Eli Lilly And Company Inhibitors of monoamine uptake
EP1666067A4 (en) * 2003-08-22 2009-07-22 Teijin Pharma Ltd MEDICAMENT WITH CHYMASE INHIBITOR AS AN ACTIVE SUBSTANCE
DE102004004928A1 (de) 2004-01-31 2005-08-18 Bayer Healthcare Ag Dibenzoxazepine II
JP5319113B2 (ja) 2004-03-26 2013-10-16 メチルジーン インコーポレイテッド ヒストンデアセチラーゼの阻害剤
US7507748B2 (en) 2004-07-22 2009-03-24 Amgen Inc. Substituted aryl-amine derivatives and methods of use
EP2942349A1 (en) 2004-12-23 2015-11-11 Deciphera Pharmaceuticals, LLC Enzyme modulators and treatments
MX2007013595A (es) 2005-05-04 2008-01-24 Renovis Inc Compuestos heterociclicos fusionados y composiciones y usos de estos.
WO2007007161A2 (en) * 2005-07-08 2007-01-18 Orchid Research Laboratories Limited Novel bio-active derivatives
WO2007120339A1 (en) 2005-12-19 2007-10-25 Genentech, Inc. Pyrimidine kinase inhibitors
CA2642406A1 (en) 2006-02-14 2007-08-23 Pfizer Products Inc. Benzoxazinone and benzoxazepinone oxazolidinones as antibacterial agents
AR061570A1 (es) 2006-06-23 2008-09-03 Smithkline Beecham Corp Compuesto de glicina sustituido en el n heteroaromatico composicion farmaceutica que lo comprende, su uso para preparar un medicamento, procedimientos para preparar dicha composicion farmaceutica y para preparar el compuesto
US7790756B2 (en) 2006-10-11 2010-09-07 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
GB0622472D0 (en) 2006-11-10 2006-12-20 Addex Pharmaceuticals Sa Novel heterocyclic derivatives
US8314087B2 (en) 2007-02-16 2012-11-20 Amgen Inc. Nitrogen-containing heterocyclyl ketones and methods of use
CA2683785A1 (en) 2007-04-13 2008-10-23 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as kinase inhibitors
WO2009049112A1 (en) 2007-10-10 2009-04-16 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
NZ585348A (en) 2007-10-19 2012-02-24 Boehringer Ingelheim Int Heterocycle-substituted piperazino-dihydrothienopyrimidines
JP4790871B2 (ja) * 2008-05-05 2011-10-12 メルク フロスト カナダ リミテツド レニン阻害剤としての3,4−置換ピペリジン誘導体
AU2009263384A1 (en) 2008-06-25 2009-12-30 Daiichi Sankyo Company, Limited Carboxylic acid compound
DE102008030091B4 (de) * 2008-06-25 2011-03-03 Resprotect Gmbh Uracilderivate und deren Verwendung
UA112897C2 (uk) * 2012-05-09 2016-11-10 Байєр Фарма Акцієнгезелльшафт Біциклічно заміщені урацили та їх застосування для лікування і/або профілактики захворювань

Also Published As

Publication number Publication date
JO3290B1 (ar) 2018-09-16
DK3045456T3 (da) 2018-01-29
BR112014028086A2 (pt) 2020-12-01
AR090994A1 (es) 2014-12-30
PT2847190T (pt) 2016-07-14
IL253950A0 (en) 2017-10-31
TN2014000470A1 (en) 2016-03-30
SI2847190T1 (sl) 2016-08-31
HK1202873A1 (en) 2015-10-09
MX2014013571A (es) 2014-12-08
TW201406744A (zh) 2014-02-16
US10300062B2 (en) 2019-05-28
US20170020876A1 (en) 2017-01-26
CN104395310A (zh) 2015-03-04
WO2013167495A1 (de) 2013-11-14
AU2017265047B2 (en) 2019-04-18
MX367599B (es) 2019-08-28
CO7131375A2 (es) 2014-12-01
EP3045456A1 (de) 2016-07-20
LT3045456T (lt) 2018-02-12
US9949977B2 (en) 2018-04-24
PT3045456T (pt) 2018-01-30
RS56784B1 (sr) 2018-04-30
ECSP14026138A (es) 2015-12-31
PL2847190T3 (pl) 2016-12-30
JP6141414B2 (ja) 2017-06-07
TWI579278B (zh) 2017-04-21
US20150148340A1 (en) 2015-05-28
US20180256576A1 (en) 2018-09-13
MX357712B (es) 2018-07-20
AU2013258223B2 (en) 2017-11-09
PH12014502496B1 (en) 2015-01-12
PH12014502496A1 (en) 2015-01-12
ES2657315T3 (es) 2018-03-02
CY1119840T1 (el) 2018-06-27
NZ701700A (en) 2016-09-30
IL253950B (en) 2019-07-31
EP2847190B1 (de) 2016-04-06
EA030383B9 (ru) 2018-12-28
CR20140513A (es) 2014-12-02
SG10202003175QA (en) 2020-05-28
HUE035462T2 (en) 2018-05-02
IL235438A (en) 2017-08-31
JP2015516000A (ja) 2015-06-04
CN104395310B (zh) 2017-05-03
CL2014003031A1 (es) 2015-03-06
CY1118900T1 (el) 2018-01-10
MY181828A (en) 2021-01-08
TWI635085B (zh) 2018-09-11
HRP20180125T1 (hr) 2018-02-23
BR112014028086B1 (pt) 2021-09-21
HUE029366T2 (en) 2017-02-28
EA031222B1 (ru) 2018-12-28
US9949978B2 (en) 2018-04-24
PL3045456T3 (pl) 2018-03-30
US20200061063A1 (en) 2020-02-27
DK2847190T3 (en) 2016-07-25
SI3045456T1 (en) 2018-03-30
AU2013258223A1 (en) 2014-11-27
CN106983751A (zh) 2017-07-28
PE20142301A1 (es) 2014-12-19
US9481672B2 (en) 2016-11-01
CU20140129A7 (es) 2015-02-26
CN106983751B (zh) 2020-01-07
EA030383B1 (ru) 2018-07-31
ZA201408146B (en) 2017-01-25
UY34797A (es) 2013-11-29
SA113340533B1 (ar) 2015-10-12
DOP2014000255A (es) 2015-02-27
JP6367421B2 (ja) 2018-08-01
EP2847190A1 (de) 2015-03-18
UA112897C2 (uk) 2016-11-10
CA2872906C (en) 2020-08-04
KR102083281B1 (ko) 2020-05-29
NO3045456T3 (sr) 2018-03-24
EP3045456B1 (de) 2017-10-25
CA2872906A1 (en) 2013-11-14
JP2017160242A (ja) 2017-09-14
AU2017265047A1 (en) 2017-12-14
AP2014008096A0 (en) 2014-12-31
TW201734007A (zh) 2017-10-01
EA201492040A1 (ru) 2015-12-30
EA201790032A1 (ru) 2017-05-31
ES2581537T3 (es) 2016-09-06
KR20150016548A (ko) 2015-02-12
HRP20160796T1 (hr) 2016-08-12
US20170020875A1 (en) 2017-01-26

Similar Documents

Publication Publication Date Title
RS54901B1 (sr) Biciklično supstituisani uracili i njihova upotreba
MD20150019A2 (ro) Alcoxipirazoli în calitate de activatori ai guanilat ciclazei solubile
PH12017501192B1 (en) Certain amino-pyridazines, compositions thereof, and methods of their use
PH12016501007A1 (en) Substituted benzamides and methods of use thereof
PH12016502037A1 (en) Certain amino-pyrimidines, compositions thereof, and methods for their use
IN2014DN07874A (sr)
MX2014014229A (es) Pirrolidina-2-carboxamidas sustituidas.
RS52270B (sr) 4-(4-cijano-2-tioaril)-dihidropirimidinon i njegova primena
RS54746B1 (sr) Indoli kao antiviralni agensi za respiratorni sincicijalni virus
MX2014013074A (es) Compuestos de n- (tetrazol-5-il) - y n- (triazol-5-il) arilcarboxamida sustituidos y su uso como herbicidas.
RS54708B1 (sr) Ariletinil derivati
MY186599A (en) Substituted pyridopyrazines as novel syk inhibitors
MY180618A (en) Pyridazinone compounds and their use as daao inhibitors
MX363987B (es) Sales de n-(tetrazol-5-il)- y n-(triazol-5-il)arilcarboxamida y uso de las mismas como herbicidas.
RS54189B1 (sr) Postupci za korišćenje inibitora alk
MX2015015786A (es) Compuestos de n-(tetrazol-5-il)- y n-(triazol-5-il) arilcarboxamida sustituidos y su uso como herbicidas.
MX2012007536A (es) Derivados de heteroarilo que contienen nitrogeno.
GEP20125393B (en) New phenylsulfamoyl benzamide derivatives as bradykinin antagonists
MY169179A (en) Novel piperidine compound or salt thereof
EA201491820A1 (ru) Новые тиенопиримидиновые производные, способы их получения и их терапевтические применения
RS53677B1 (sr) Jedinjenja triazolopiridina
MX2016002738A (es) Compuestos farmaceuticos.
RS53928B1 (sr) Herbicidna jedinjenja
MX2011008360A (es) Derivados de piridazinona sustituida con heteroarilo.
HRP20171273T1 (hr) Spoj dikarboksilne kiseline